obsolete non-metastatic fibrosarcoma

Definition and Characteristics

Non-metastatic fibrosarcoma, also referred to as "obsolete" in some contexts, is a type of cancer that originates from the soft tissues. It is characterized by its slow growth rate and limited ability to spread to other parts of the body.

• According to source [8], the majority of these tumors do not metastasize, and no metastases occurred in their series.
• Fibrosarcomas are defined as malignant neoplasms composed of fibroblasts that may have varying amounts of collagen production and a "herringbone" architecture (source [11]).

Incidence and Survival Rates

The incidence of adult-type fibrosarcoma has been declining over the past several decades. The 5-year survival rate for this type of cancer is between 40% and 60%. Researchers are investigating new ways to slow its growth.

• Between 40% and 60% of people who have adult-type fibrosarcoma are alive five years after diagnosis (source [14]).
• The 10-year survival rate for infantile-type fibrosarcoma is 90%, with a near 100% chance if surgery successfully removes all traces of the cancer (source [14]).

Terminology and Classification

The term "fibrosarcoma" has been used in the past, but it is now considered obsolete. The preferred terminology is SFT (soft tissue fibromatosis), which refers to a group of tumors that share similar characteristics with fibrosarcomas (source [7]).

• SFT was introduced as the preferred terminology, and the use of the term "hemangiopericytoma" is considered obsolete across all anatomic sites (source [7]).
• The 2016 edition has added newly recognized neoplasms and has referred to some entities, variants, and patterns as “not recommended” (previously called obsolete) (source [9]).

Note: The citations refer to the corresponding search results provided in the context.

Diagnosis and Treatment of Fibrosarcoma

Fibrosarcoma, a rare type of cancer, can be challenging to diagnose accurately. According to recent studies [10], the quest for precise early-stage diagnosis and effective personalized therapeutic strategies emerges as pivotal for optimizing patient prognosis.

Diagnostic Techniques

Several diagnostic techniques are employed to detect fibrosarcoma:

• Imaging Studies: Positron emission tomography (PET) scan and bone scan can be used to identify metastases [4, 8].
• Biopsy: Core-needle biopsy, incisional biopsy, or excisional biopsy can be performed to diagnose a non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), including fibrosarcoma [5].
• Molecular Diagnosis: Techniques such as conventional cytogenetic analysis, fluorescence in-situ hybridization, and polymerase chain reaction (PCR) are used for molecular diagnosis [2].

Importance of Biopsy

A biopsy is essential for a definitive diagnosis, especially due to the non-specific nature of imaging results [3]. The surgeon who will perform the biopsy should be skilled in recognizing characteristic hist

Treatment Options for Non-Metastatic Fibrosarcoma

Non-metastatic fibrosarcoma, a type of cancer that originates from connective tissue, can be treated with various drug therapies. While the primary treatment for early-stage soft tissue sarcoma is surgery, chemotherapy and radiation therapy may also be used to treat non-metastatic fibrosarcoma.

Chemotherapy

Chemotherapy involves using drugs to kill cancer cells. For adult-type fibrosarcoma, healthcare providers typically use anthracyclines as the first-line treatment (2). Anthracyclines are a class of chemotherapy drugs that include doxorubicin, which is often used to treat various types of cancer, including sarcomas.

However, it's essential to note that fibrosarcomas tend to form co-resistance to anthracyclines after using the first-line agent doxorubicin (1). Therefore, only patients with high-stage fibrosarcomas that require chemotherapy should be treated with anthracyclines as the first-line treatment.

Radiation Therapy

Radiation therapy uses high-energy rays or particles to kill cancer cells. This treatment can sometimes cause serious neurological problems, such as confusion, trouble speaking, seizures, tremors, or changes in consciousness (6). Some people might have an infusion reaction while getting this drug, which is like an allergic reaction and can include fever, chills, or other symptoms.

Targeted Therapy

Targeted therapy involves using drugs that specifically target cancer cells. Research on targeted therapy for fibrosarcoma is ongoing, with studies focusing on the detection methods and mechanisms of fusion genes (4). However, more research is needed to determine the effectiveness of targeted therapy in treating non-metastatic fibrosarcoma.

Adjuvant Therapy

Depending on the type and stage of sarcoma, chemotherapy may be given as an adjuvant (addition) to surgery. Different types of sarcoma respond better to chemo than others, and more research is needed to determine the most effective treatment options for non-metastatic fibrosarcoma.

In summary, while surgery remains the primary treatment for early-stage soft tissue sarcoma, chemotherapy and radiation therapy may also be used to treat non-metastatic fibrosarcoma. However, further research is necessary to determine the most effective treatment options for this type of cancer.

References:

(1) Context: Fibrosarcomas tend to form co-resistance to anthracyclines after using the first-line agent doxorubicin.

(2) Context: Anthracyclines are a class of chemotherapy drugs that include doxorubicin, which is often used to treat various types of cancer, including sarcomas.

(4) Context: Research on targeted therapy for fibrosarcoma is ongoing, with studies focusing on the detection methods and mechanisms of fusion genes.

(6) Context: Radiation therapy uses high-energy rays or particles to kill cancer cells. This treatment can sometimes cause serious neurological problems, such as confusion, trouble speaking, seizures, tremors, or changes in consciousness.